<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="9150">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 09, 2023</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT05704283</url>
  </required_header>
  <id_info>
    <org_study_id>22-006606</org_study_id>
    <secondary_id>NCI-2023-00106</secondary_id>
    <secondary_id>P30CA015083</secondary_id>
    <nct_id>NCT05704283</nct_id>
  </id_info>
  <brief_title>3D Ultrasound for the Imaging of Axillary Lymph Nodes in Patients With Breast Cancer</brief_title>
  <official_title>3D Ultrasound Imaging of the Axillary Lymph Nodes</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Mayo Clinic</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Cancer Institute (NCI)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>Mayo Clinic</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>Yes</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This early phase I studies how well a new 3D ultrasound (3D-US) imaging technology works in&#xD;
      evaluating axillary lymph nodes in patients with breast cancer. Ultrasound uses&#xD;
      high-frequency sound waves to generate images of the body.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      PRIMARY OBJECTIVES:&#xD;
&#xD;
      I. Conducting a pilot study to optimize the in vivo performance of the newly developed&#xD;
      three-dimensional (3D)-ultrasound (US) technology.&#xD;
&#xD;
      II. Evaluate the performance of the new 3D-US technique in differentiating benign from&#xD;
      malignant axillary lymph nodes (ALNs).&#xD;
&#xD;
      III. Compare the performance of the new 3D-US method with conventional two-dimensional&#xD;
      (2D)-US for localizing the clipped ALNs.&#xD;
&#xD;
      OUTLINE:&#xD;
&#xD;
      Patients undergo 3D-US on study. Patients who have an ALN clip placed and undergoing&#xD;
      neoadjuvant chemotherapy undergo imaging of the clipped node before surgery.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">February 14, 2023</start_date>
  <completion_date type="Anticipated">April 1, 2025</completion_date>
  <primary_completion_date type="Anticipated">April 1, 2025</primary_completion_date>
  <phase>Early Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Diagnostic</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Axillary lymph node (ALN) diagnosis by radiologist (benign or malignant) (Aim 2)</measure>
    <time_frame>Up to 2 years</time_frame>
    <description>Will characterize the ALN as benign or malignant by reviewing images from each imaging technique based on clinical criteria including node size, shape, margin, cortical thickness, stiffness, and vascularity obtained from B-mode, shear wave elastography, and Doppler imaging. Histopathology results will be used as the ground truth to measure the sensitivity and specificity of each ultrasound technology for distinguishing between benign and malignant ALNs. The overall agreement of the new 3dimensional (D)-ultrasound (US) method with the biopsy result will be compared to that for 2D-US using McNemar's test. For clipped ALNs, the performance of 2D and 3D-US will be compared for localizing the clips. A numerical score system will be used for quantifying the performance of clip localization, with significant improvement in scores determined using the Freeman-Halton extension of the Fisher exact test. In all cases, we will consider two-tailed p &lt; 0.05 as statistically significant.</description>
  </primary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">60</enrollment>
  <condition>Breast Carcinoma</condition>
  <arm_group>
    <arm_group_label>Diagnostic (3D-US)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients undergo 3D-US on study. Patients who have an ALN clip placed and undergoing neoadjuvant chemotherapy undergo imaging of the clipped node before surgery.</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Ultrasound Imaging</intervention_name>
    <description>Undergo 3D-US</description>
    <arm_group_label>Diagnostic (3D-US)</arm_group_label>
    <other_name>2-Dimensional Grayscale Ultrasound Imaging</other_name>
    <other_name>2-Dimensional Ultrasound Imaging</other_name>
    <other_name>2D-US</other_name>
    <other_name>Ultrasonography</other_name>
    <other_name>Ultrasound</other_name>
    <other_name>Ultrasound Test</other_name>
    <other_name>Ultrasound, Medical</other_name>
    <other_name>US</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Female patients with breast cancer and scheduled to have axillary lymph node biopsy as&#xD;
             per routine clinical care.&#xD;
&#xD;
          -  Age of 18 or older.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Vulnerable subjects such as prisoners and adults lacking capacity to consent.&#xD;
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Shigao D Chen</last_name>
    <role>Principal Investigator</role>
    <affiliation>Mayo Clinic in Rochester</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Mayo Clinic in Rochester</name>
      <address>
        <city>Rochester</city>
        <state>Minnesota</state>
        <zip>55905</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Clinical Trials Referral Office</last_name>
      <phone>855-776-0015</phone>
      <email>mayocliniccancerstudies@mayo.edu</email>
    </contact>
    <investigator>
      <last_name>Shigao D. Chen, M.D.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>March 2023</verification_date>
  <study_first_submitted>January 19, 2023</study_first_submitted>
  <study_first_submitted_qc>January 19, 2023</study_first_submitted_qc>
  <study_first_posted type="Actual">January 30, 2023</study_first_posted>
  <last_update_submitted>March 30, 2023</last_update_submitted>
  <last_update_submitted_qc>March 30, 2023</last_update_submitted_qc>
  <last_update_posted type="Actual">April 3, 2023</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Mayo Clinic</investigator_affiliation>
    <investigator_full_name>Shiago Chen</investigator_full_name>
    <investigator_title>Principal Investigator</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Breast Neoplasms</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

